Acrivon Therapeutics, Inc. - 8-K Filing

Acrivon Therapeutics reports Q3 2026 net loss of $17.9 million and announces strategic expansion into immunology and inflammation. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ACRV

Read the full article at SEC EDGAR

More Regulatory news